Counterregulatory hormone responses after long-term continuous subcutaneous insulin infusion with lispro insulin

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

To determine whether the long-term use of insulin lispro (LP) affects the counterregulatory hormone response to hypoglycemia.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Patients were randomized to LP or human regular insulin (HR) for 3 months and then crossed over to the other insulin for an additional 3 months.

Counterregulatory hormone responses to a stepped hypoglycemic clamp (consecutive glucose levels in mmol/l: 4.2; 3.5; 2.8, each for 1 h) were evaluated at the end of each treatment period.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Random assignment meant chance, not the researchers, decided who got Insulin Lispro and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Insulin Lispro, so expectations could not easily colour the readings.

Each person switched between Insulin Lispro and the comparison at some point, usually with a gap in between.

The methods mention a period of 3 months.

All meal boluses were given 0-5 min before breakfast, lunch, and dinner.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Body Mass Index, Diabetes Mellitus, Type 1, Epinephrine, Glucagon, Glucose Clamp Technique and Glycated Hemoglobin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Lispro over 3 months.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1998 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.